While we wait......, page-4

Iv'e been busy putting together a calendar of Biotechs entering Phase I and II, completed Phase I and II , these are the inflection points I'm generally in for,, I'm only on two out of 14 for the long haul the other 12 are just 10% and 20% gains and I'm out .. BOT is one of the two long hauls for me... I just see so much upside here and not as risky as when I first came on board,,, Derma on the matrix of complexity is a long way down under ingestion and Medical Procedure ,,, with the Derma market really held by two to three players it will be a race upon positive results to who can secure BOT technology the fastest,,, it may be a split license,,, or some that don't play well with others may just identify the risk BOT tech signifies to them,,,and just want the whole enchilada .. plus they have the pocket depth to play...